Table 1 Assessment of hub gene expression through the analysis of RNAseq data and microarray metadata.

From: A Comprehensive multi-network analysis of ceRNAs and transcription factors for papillary thyroid carcinoma diagnosis and prognosis

Genes

RNAseq data

Microarray metadata

I – N

II- N

III –N

IV –N

P-N

logFC

FDR

logFC

FDR

logFC

FDR

logFC

FDR

logFC

FDR

PKMYT1

1.8

9.3e-26

1.4

4.9e-10

1.9

9.3e-24

2.1

2e-23

0.21

1.8e-08

RMI2

1.8

5.6e-27

1.5

6.9e-13

1.8

1.5e-24

1.9

4.2e-22

1.02

3.7e-24

ASF1B

1.9

1.3e-25

1.5

1.9e-10

1.9

2.3e-23

2

4.4e-21

0.58

2.3e-12

CDT1

1.9

1.5e-26

1.7

6.5e-14

2

3.4e-25

2.2

2.3e-23

0.49

3.7e-14

E2F1

2.2

4.4e-32

2.1

2.5e-20

2.3

1.2e-30

2.4

5.9e-26

0.3

7.1e-13

TK1

1.8

1.6e-22

1.6

3.3e-12

1.9

1.2e-21

2

1e-19

0.62

9.6e-13

  1. Hub genes were differentially expressed according to microarray metadata analysis. Hub genes also showed differential expression at stages I to IV after RNAseq data analysis. Microarray datasets were retrieved from the NCBI-GEO public repository and RNAseq data from the publicly available TCGA database.
  2. N: normal; I: stage I; II: stage II; III: stage III; IV: stage IV; P: papillary thyroid cancer; logFC: log2-fold change; FDR: false discovery rate; PKMYT1: protein kinase membrane-associated tyrosine/threonine 1; RMI2: RecQ-Mediated Genome Instability 2. ASF1B: anti-silencing function 1B histone chaperone, CDT1: chromatin licensing and DNA replication factor 1, TK1: thymidine kinase 1, E2F1: E2F transcription factor 1.
Back to article page